One of the most wannabe goals for any industry is to accomplish maximum return on investment (ROI) which can be achieved with the finest Ultraviolet (UV) Packaging Printing Market research report. The main research methodology utilized by DBMR research team is data triangulation which entails data mining, analysis of the impact of data variables on the market, and primary validation. Market insights of this report will direct for an actionable ideas, improved decision-making and better business strategies. The Ultraviolet (UV) Packaging Printing Market report is mainly delivered in the form of PDF and spreadsheets while PPT can also be provided depending upon clients request. To achieve an inevitable success in the business, this Ultraviolet (UV) Packaging Printing Market report plays a significant role.

Market Analysis and Insights of Global Ultraviolet (UV) Packaging Printing Market

Ultraviolet (UV) packaging printing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to grow at a CAGR of 9.5% in the above-mentioned forecast period.

With the market info provided in the Ultraviolet (UV) Packaging Printing Market report, it has become easy to gain global perspective for the international business. Focus groups and in-depth interviews are included for qualitative analysis whereas customer survey and analysis of secondary data has been carried out under quantitative analysis. This business report is a definite study of the Ultraviolet (UV) Packaging Printing Market industry which explains what the market definition, classifications, applications, engagements, and global industry trends are. This market research report acts as a very significant constituent of business strategy. Ultraviolet (UV) Packaging Printing Market report proves to be a sure aspect to help grow your business.

Get Exclusive PDF Sample Copy of the MarketReport to understand the structure of the complete Study Including Full TOC, Tables & Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ultraviolet-uv-packaging-printing-market

Packaging printing technology is used to enclose and protect products before they are distributed, stored, sold, or used. Though the primary purpose of packaging is to store products, packaging printing technology also serves as a means of product and brand promotion and aids in the development of strong consumer relationships. The UV printing is a unique method of digital printing that uses ultraviolet (UV) light to dry or cure ink, adhesives, or coatings almost as soon as they contact the paper, aluminium, foam board, or acrylic.

Market Scope and Global Ultraviolet (UV) Packaging Printing Market

Some of the major players operating in the ultraviolet (UV) packaging printing market report are Mondi, Sonoco Products Company, Graphic Packaging International, LLC, Quad/Graphics, Inc., Amcor plc, Constantia Flexibles, Quantum Packaging Store, WS Packaging Group, Inc., TOPPAN PRINTING CO., LTD., Duncanprint., Belmont Packaging Limited., Shree Arun Packaging Company Private Limited., ZAO SPb Model Typography, Coveris, and Quantum Packaging Store among others.

GlobalUltraviolet (UV) Packaging PrintingMarket Scope and Market Size

Ultraviolet (UV) packaging printing market is segmented on the basis of printing technology, material and application. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

The ultraviolet (UV) packaging printing market is segmented in terms of market value, volume, market opportunities and niches into multiple applications. The application segment for ultraviolet (UV) packaging printing market includesfood and beveragesproducts, household and cosmetic products, pharmaceutical products and adhesives and sealants.

Want a Sneak Peek into the Market Access the TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-ultraviolet-uv-packaging-printing-market

Radical Coverage of the Ultraviolet (UV) Packaging Printing Market:

Key Questions Addressed in the Report:

Which segments are expected to show significant growth over the forecast period?

What is the forecast estimation of Ultraviolet (UV) Packaging Printing Market growth?

What are the factors that are likely to restrain the growth of the market?

What are the key driving factors of industry growth?

Which region is expected to dominate in the forecast period?

Which markets are significantly positive for developing businesses?

What is the expected growth rate of the industry throughout the forecast period?

Which market segments are expected to boost the growth of the industry?

Who are the dominating players of the Ultraviolet (UV) Packaging Printing Market?

What are the strategic business plans undertaken by the key players of the industry?

Access for Full [emailprotected] https://www.databridgemarketresearch.com/reports/global-ultraviolet-uv-packaging-printing-market

Browse other related reports:

https://www.marketwatch.com/press-release/organic-saffron-market-industry-analysis-key-drivers-business-strategy-opportunities-and-forecast-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/shooting-ranges-market-size-share-industry-trends-analysis-report-by-usage-by-industry-vertical-by-regional-outlook-and-forecast-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/squash-rackets-market-business-insights-size-trends-future-assessment-technology-advancements-and-forecast-by-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/disposable-slippers-market-witness-widespread-expansion-of-industry-growth-regional-analysis-and-forecast-till-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/television-services-market-emerging-trends-revenue-competitive-landscape-regional-overview-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/smart-connected-pet-collar-market-size-industry-opportunities-growth-competitive-landscape-recent-developments-and-forecast-by-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/shoe-deodorizer-market-business-insights-size-trends-future-assessment-technology-advancements-and-forecast-by-2028-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/trigger-sprayer-market-size-share-trends-demand-growth-statistics-revenue-and-insights-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/food-starter-culture-market-research-report-with-opportunities-and-strategies-to-boost-growthcovid-19-impact-and-recovery-2022-08-02?mod=search_headline

https://www.marketwatch.com/press-release/cocoa-and-chocolate-coating-market-outlook-2028-top-companies-trends-and-growth-factors-details-for-business-development-2022-08-02?mod=search_headline

Why Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delves into the markets acrossAsia,North America,South America, andAfricato name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate

Contact Us:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475E-Mail:[emailprotected]

Continued here:

Ultraviolet (UV) Packaging Printing Market to Receive Progressing CAGR of 9.5% by 2029 - Digital Journal

What happened

Shares of Palantir Technologies (PLTR) popped higher on Thursday morning, defying the general market downturn. The stock jumped as much as 4.9% but was up about 1.4% as of 3:12 p.m. ET -- even as the three major indexes got crushed, as the S&P 500and the Nasdaq Composite plunged 2.6% and 3.5%, respectively.

The catalyst that sent the machine learning software and data mining specialist higher was news the company will continue its work with the U.S. Army on several fronts.

First, Palantir announced that its contract with the U.S. Army Research Laboratory has been extended. The company's work will "support all branches of the Armed Services, Joint Staff, and Special Forces as they test, utilize, and scale artificial intelligence and machine learning capabilities across the Department of Defense." The one-year contract extension is worth $229 million.

Furthermore, Palantir will join BigBear.ai (BBAI) in implementing the Global Force Information Management System, the Army's enterprise-wide intelligent automation platform that provide leadership with a "holistic view of its global force structure," helping the service "man, equip, train, ready, and resource the Army more effectively." The nine-month contract is valued at $14.8 million, but since BigBear is the primary contractor, Palantir's cut of the proceedings isn't immediately clear.

Palantir has a long history of partnering with U.S. government and military agencies to deploy software and data mining solutions, so these latest contract announcements aren't too much of a surprise. However, the key to Palantir's long-term success will be the expansion of its commercial business, which is currently being buffeted by macroeconomic headwinds.

The stock has never been cheap, and even after the stock's recession-induced 70% decline, Palantir Technologies valuation is still a bit frothy, selling at roughly 9 times this year's sales. Some would argue that its price-to-sales ratio is too high for a company that expects to grow its revenue by 24% this year. On the other hand, Palantir's outlook doesn't include any new government contracts, so given this new business, its forecast is likely conservative.

Danny Vena has positions in Palantir Technologies Inc. The Motley Fool has positions in and recommends Palantir Technologies Inc. The Motley Fool has a disclosure policy.

Continue reading here:

Why Palantir Technologies Stock Popped on Thursday - The Motley Fool

Ethical approval

The local animal care approved the study protocol and use committee (ComEth EnvA-Upec-ANSES, reference: 11-0041, dated July 12, 2011), and protocols were conducted following the EU regulation (no 2010/63/UE). Owners and riders provided their informed consent before the start of sampling procedures with the animals. The horses (Equus caballus) used in this research study were pure-breed or half-breed Arabian (three females, one male, and seven geldings; age: 101.69 years old).

Eleven endurance horses were selected from a cohort previously used in our team6,24,25,70. All equine athletes started training for endurance competitions at age 4 and presented a similar training history, level of physical fitness, and training environment. The 11 horses were selected due to the following criteria: (1) enrollment in the same 160km endurance category; (2) blood sample collection before and after the race; (3) feces collection before the race; (4) absence of gastrointestinal disorders during the four months before enrollment; (5) absence of antibiotic treatment during the four months before enrollment and absence of anthelmintic medication within 60 days before the race, and (6) a complete questionnaire about diet composition and intake.

Subject metadata, including morphometric characteristics and daily macronutrient diet intake records, is depicted in Supplementary Data1. Daily nutrient intake calculations are described elsewhere24.

The endurance race was split into ~3040km phases. At the end of each phase, veterinarians checked horses (referred to as a vet gate). The heart recovery time was the primary criterion evaluated at the vet gate as it is shown to be an excellent complement to a physical assessment of an individual. The heart rate was measured at each vet gate by the riders and a veterinarian using a heart rate meter and a stethoscope. Any horse deemed unfit to continue (due to a heart rate above 64bpm after 20min of recovery) was immediately withdrawn from the event.

It should be noted that the time interval between arrival at the vet gate and the time needed to decrease the heart rate below 64bpm was counted as part of the overall riding time. Therefore, the cardiac recovery time was calculated as the difference between the arrival time (at the end of the phase) and the time of veterinary inspection (referred to as the time in by the FEI endurance rules). The average speed of each successive phase was calculated at the vet gate.

Changes in these three variables during endurance events have been shown to predict whether a horse is aerobically fit or not71. We consider these variables to estimate cardiovascular capacity linked to performance capability and achievement. Therefore, these three variables were first scaled through a Z-score; that is, the number of standard deviation units a horses score is below or above the average score. Such a computation creates a unitless score that is no longer related to the original units of analysis (e.g., minutes, beats, Km/h). It measures the number of standard deviation units and can more readily be used for comparisons. A composite based on such Z-scores was then created to estimate cardiovascular fitness. Specifically, the composite() function of the multicon R package (v.1.6) was used to develop a unit-weighted composite of the three variables listed above.

The kinship272 (v.1.8.5) R package was used to calculate the pedigree kinship matrix of all individual pairs, plot the pedigree, and trim the pedigree object. The kinship coefficient for any two subjects was calculated as the probability that an allele chosen at random for both subjects at a given locus is identical-by-descent, that is, inherited from a common ancestor72. The pedigree was calculated using six generations back for the 11 Arabian horses of the study. The pedigree kinship matrix was then visualized using the plot_popkin() function from the popkin (v.1.3.17) R package. The inbr_diag() function was used to modify the kinship matrix, with inbreeding coefficients along the diagonal, preserving column and row names.

Blood samples were collected from each horse the day before the event (Basal, T0) and immediately after the end of the competition (T1) for transcriptomic, biochemical, metabolomic, and acylcarnitine assays. As described elsewhere24, pretreatment of the blood samples was carried out immediately after the collection because field conditions provided access to refrigeration and electrical power supply. Briefly, blood samples for RNA extraction were collected using Tempus Blood RNA tubes (Thermo Fisher) and stored at 80C. Whole blood samples were taken in EDTA tubes (10mL; Becton Dickinson, Franklin Lakes, NJ, USA) to determine biochemical parameters, while for the metabolome profiling, the sodium fluoride and oxalate tubes were used to inhibit further glycolysis that may increase lactate levels after sampling. Then, clotting time at 4C was strictly controlled for all samples to avoid cell lyses that affect metabolome components. After clotting at 4C, the plasma was separated from the blood cells, transported to the lab at 4C, and frozen at 80C (no more than 5h later, in all cases). Concerning the acylcarnitine, blood samples were collected in plain tubes. After clotting, the tubes were centrifuged, and the harvested serum was stored at 4C for no more than 48h and subsequently stored at 80C.

According to the manufacturers instructions, total RNAs were isolated using the Preserved Blood RNA Purification Kit I (Norgen Biotek Corp., Ontario, Canada). RNA purity and concentration were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher), and RNA integrity was assessed using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). All the 22RNA samples were processed. The transcriptome microarray data production, pre-processing, and analysis are depicted in Mach et al.25.

Transcriptome profiling was performed using an Agilent 4X44K horse custom microarray (Agilent Technologies, AMADID 044466). All of the steps are detailed here73,74. We refer to our previous work for more details on the pre-processing, normalization, and application of linear models25. Given our interest in understanding the role played by mitochondria during exercise, the set of 801 differentially expressed mitochondrial genes reported by our team25 was selected for the downstream steps of analysis (Supplementary Data15).

As described elsewhere24,70, the plasma metabolic phenotype of endurance horses was obtained from 1H NMR spectra at 600MHz. The 1H NMR spectra were acquired at 500MHz with an AVANCE III (Bruker, Wissembourg, France) equipped with a 5mm reversed QXI Z-gradient high-resolution probe. Further details on sample preparation, data acquisition, quality control, spectroscopic data pre-processing, and data pre-processing, including bin alignment, normalization, scaling, and centering, are broadly discussed elsewhere75. Details on metabolite identification are described in our previous work24,25.

Sera were assayed for total bilirubin, conjugated bilirubin, total protein, creatinine, creatine kinase, -hydroxybutyrate, and aspartate transaminase (ASAT), -glutamyltransferase and serum amyloid A levels on an RX Imola analyzer (Randox, Crumlin, UK).

As a proxy for mitochondrial -oxidation, the serum acylcarnitine profiles were produced and analyzed as described elsewhere6. In the positive mode, free carnitine and 27 acylcarnitines were analyzed for their butyl ester derivatives by electrospray tandem mass spectrometry (ESI-MS-MS) on a triple quadrupole mass spectrometer (Xevo TQ-S Waters, Milford, MA, USA) using deuterated water.

Fresh fecal samples were obtained while monitoring the horses before the race. One fecal sample from each animal was collected immediately after defecation24,76, and three aliquots (200mg) were prepared. The dehydration experienced by most horses after the race altered intestinal motility and feces shedding, making it impossible to recover the feces immediately after the race.

Aliquots for SCFA analysis and DNA extraction were snap-frozen.

SCFA levels were determined by gas chromatography using the method described elsewhere77.

Total DNA from the 11 samples was extracted from ~200mg of fecal material using the EZNA Stool DNA Kit (Omega Bio-Tek, Norcross, Georgia, USA) following the manufacturers instructions. DNA was then quantified using a Qubit and a dsDNA HS assay kit (Thermo Fisher).

As detailed in our previous studies24,25, concentrations of bacteria, anaerobic fungi, and protozoa in fecal samples were quantified by qPCR using a QuantStudio 12K Flex platform (Thermo Fisher Scientific, Waltham, USA). Primers for real-time amplification of bacteria (FOR: 5-CAGCMGCCGCGGTAANWC-3; REV: 5-CCGTCAATTCMTTTRAGTTT-3), anaerobic fungi (FOR: 5-TCCTACCCTTTGTGAATTTG-3; REV: 5-CTGCGTTCTTCATCGTTGCG-3) and protozoa (FOR: 5-GCTTTCGWTGGTAGTGTATT-3; REV: 5-CTTGCCCTCYAATCGTWCT-3). Details of standard dilutions series, the thermal cycling conditions, and the estimation of the number of copies are detailed elsewhere24,25.

A detailed description of the DNA isolation process, V3V4 16S rRNA gene sequencing-PCR amplification, is presented by our group19,20,24,25,76,78,79. A negative control sample alongside biological samples at the DNA extraction and PCR steps was considered in attempts to control DNA contamination before and after sequencing. In addition, contamination was minimized through laboratory techniques such as UV irradiation of material, ultrapure water, the DNA-free Taq DNA polymerase, and the separation of pre-and post-PCR areas.

The Divisive Amplicon Denoising Algorithm (DADA) was implemented using the DADA2 plug-in for QIIME 2 (v.2021.2) to perform quality filtering and chimera removal and to construct a feature table consisting of read abundance per amplicon sequence variant (ASV) by sample80. Taxonomic assignments were given to ASVs by importing Greengenes 16S rRNA Database (release 13.8) to QIIME 2 and classifying representative ASVs using the naive Bayes classifier plug-in81. The phyloseq (v.1.36.0)82, vegan (v.2.5.7)83, and microbiome (v.1.14.0) packages were used in R (v.4.1.0) for the downstream steps of analysis. A total of 364,026 high-quality sequence reads were recovered for the 11 horses of the study (mean per subject: 33,093(pm)17,437, range: 12,05262,670). Reads were clustered into 5412 chimera- and singleton-filtered ASVs at 99% sequence similarity. The genera taxonomic assignments and counts for each individual are presented in Supplementary Data10).

The negative control sample did not yield a band on the agarose gel, and the concentration of the purified amplicon was undetectable (<1ng/L). Nevertheless, the decontam (v.1.14.0) R package was used to identify and visualize possible contaminating DNA features in the negative control sample. The function isContaminnat() was used to determine the distribution of the frequency of each contaminant feature as a function of the input DNA concentration. Only 6 ASV were statistically classified (p<0.05) as contaminants, although their frequency plots showed they were non-contaminants (Supplementary Fig.11).

Metagenomic sequencing was performed using the same DNA extractions. For each individual, a paired-end metagenomic library was prepared from 100ng of DNA using the DNA PCR-free Library Prep Kit (Illumina, San Diego, CA, USA). The size was selected at about 400bp. The pooled indexed library was sequenced in an Illumina HiSeq3000 using a paired-end read length of 2150pb with the Illumina HiSeq3000 Reagent Kits at the PLaGe facility (INRAe, Toulouse).

Raw metagenomic reads were quality-trimmed, assembled, binned, and annotated using the ATLAS pipeline, v.2.4.484. In short, using tools from the BBmap suite v.37.9985, reads were quality trimmed with ATLAS parameters: preprocess_minimum_base_quality=10, preprocess_minimum_passing_read_length=51, preprocess_minimum_base_frequency=0.05, preprocess_adapter_min_k=8, preprocess_allowable_kmer_mismatches=1, and the preprocess_reference_kmer_match_length=27. The contamination from the horse genome (available at NCBI sequence archive with the accession number GCA_002863925.1; Equus_caballus.EquCab3.0) was filtered out using the following settings: contaminant_max_indel=20, contaminant_min_ratio=0.65, contaminant_kmer_length=13, contaminant_minimum_hits=1, and contaminant_ambiguous=best. Reads were error corrected and merged before assembly with metaSPAdes v.3.13.186 with the subsequent parameters: spades_k=auto, prefilter_minimum_contig_length=300, minimum_average_coverage=1, minimum_percent_covered_bases=20, and minimum_contig_length=500 after filtering. QUAST 5.0.287 was used to evaluate the quality of each sample assembly. Since a high diversity between individuals was described through 16S rRNA amplicon analysis, we first assembled each sample independently. Contigs from single samples were clustered into metagenomic bins using MetaBAT 2 (v.2.14)88 with the following parameters: sensitivity=sensitive, min_contig_length=1500 and Maxbin 2.0v.2.2.789 with the parameters set to max_iteration=50, prob_threshold=0.9, and min_contig_length=1000. Contig predictions were combined using DAS Tool v.1.1.2-190 with diamond engine and score_threshold set to 0.5.

ATLAS configuration file, summaries of individual samples quality control, contigs from the individuals, and detected bins are available at the INRAE data repository (https://doi.org/10.15454/NGBSPC)91 and are contained in the files ATLAS_config.yalm, ATLAS_dag.pdf, notebook.html, ATLAS_QC_report.html, and ATLAS_bin_report_DASTool.html.

Assembly statistics for the predicted MAGs such as completeness, redundancy, size, number of contigs, contig N50, length of the longest contig, average GC content, and the number of predicted genes were computed using the lineage workflow from CheckM v.1.1.392. MAGs were designated as near-complete drafts if they had completeness 90%, redundancy <5%, transfer RNA gene sequences for at least 18 unique amino acids, or medium-quality drafts if they had completeness 50% and a redundancy <10%. A summary of the assembly statistics for the predicted MAGs is available at the INRAE data repository: https://doi.org/10.15454/NGBSPC91 as ATLAS_assembly_report.htlm.

Because the same MAG may be identified in multiple samples, dRep v.2.2.293 was used to obtain a non-redundant set of MAGs by clustering genomes to a defined average nucleotide identity (ANI) and returning the representative with the highest dRep score in each cluster. The parameters used were set to ANI=0.95, overlap=0.6, length=5000, completeness=50, contamination=10, and N50=0.5. Only the highest-scoring MAG from each secondary cluster was retained as the winning genome in the dereplicated set. The abundance of each MAG was then quantified across samples by mapping the reads to the non-redundant MAGs using the BBmap suite v.37.9985 (pairlen=100, minid=0.9, mdtag=t, xstag=fs, nmtag=t, sam=1.3, ambiguous=best, secondary=t, saa=f, maxsites=10). The sample-specific median coverage of each MAG was then computed using pileup within BBMap with default parameters.

For the taxonomic annotation, ATLAS predicted the genes of each MAG sequence using Prodigal v.2.6.394 with single-mode and closed-end parameters. The taxonomy of the predicted MAGs was inferred using the genome taxonomy database (GTDB-Tk)43 (v.5.0, release 95 (July 17, 2020)). As such, GTDB-Tk taxonomy names were used throughout this paper. In addition, domain-specific trees incorporating the predicted MAGs were inferred by constructing a maximum-likelihood tree using the de novo workflow in GTDB-Tk v.5.0 with the following parameters: --bacteria | --archaea, min_perc_aa=50, prot_model=WAG. Trees were visualized using ggtree (v.3.0.2) in the R package.

To assess the contribution of the constructed MAGs to the functional potential of the gut microbiome, the predicted gene and proteins extracted by Prodigal during the CheckM pipeline were compared to the EggNOG database 5.0 using eggnog-mapper (v2.0.1). KEGG annotation (Kyoto Encyclopedia of Genes and Genomes) and CAZymes annotation (Carbohydrate-active Enzyme) were extracted from this output. Since the detection of KOs and CAZymes families is likely influenced by sequencing depth, their relative abundance was normalized to the abundance of the MAG they derived from. Pathways attributed to each KO were annotated from the KEGG database (downloaded 23-October-2021; https://www.genome.jp/brite/ko00001).

The uniqueness of our predicted MAG catalog was confirmed by dereplicating them with the 121 MAGs produced by Gilroy et al.44 and three reported by Youngblut et al.45 using dRep v.3.2.093 with parameters: P_ani=0.9, S_algorithm ANImf, S_ani=0.99, clusterAlg average, cov_thresh=0.1, coverage_method larger. dRep performed pairwise genomic comparisons by sequentially applying an estimation of genome distance and an accurate measure of average nucleotide identity. Visualizing and comparing highly similar genomes were performed using the CGView family of tools (http://wishart.biology.ualberta.ca/cgview/).

The establishment and assessment of the quality and representation of the microbiome gene catalog were performed through the metagenomic ATLAS pipeline (v.2.4.4)84. As described above, we first assembled the clean reads into longer contigs.

Genes were predicted by Prodigal v.2.6.3 and then clustered using linclust95 to generate a non-redundant gene catalog. Redundant genes were removed with linclust using the following parameters: minlength_nt=100, minid=0.95, coverag=0.9, and subsetsize=500,000. The quantification of genes per sample was done through the combine_gene_coverages() function in the ATLAS workflow, which aligned the high-quality clean reads to the gene catalog using the BBmap suite v.37.9985 (minid=0.95, mdtag=t, xstag=fs, nmtag=t, sam=1.3, ambiguous=all, secondary=t, saa=f, maxsites=4). Taxonomic and function annotations were done based on the EggNOG database 5.0 using eggnog-mapper (v.2.0.1) (emapper.pyannotate_hits_table {input.seed}no_file_comments). The eggNOG numbers corresponding to CAZymes based on homology searches to the CAZyme database were retrieved from these. We used the derived eggNOG abundance matrix to obtain a CAZyme profile per sample. Similarly, KEGG annotation was recovered from the EggNOG output. KEGG gene IDs were mapped to KEGG KOs and used to get the KEGG functional pathway hierarchy. Furthermore, using mmseqs2 (v.13.45111) to find genes at a 95% similarity threshold and 80% overlap, we compared our gene catalog with a previously published gene catalog containing ~4 million genes30. The parameters used were the following: easy-search --search-type 3 --min-seq-id 0.95 --cov-mode 0 -c 0.8 --threads 16 --alignment-mode 3 --max-seq-len 100000.

The annotated gene catalog fasta file is deposited at DDBJ/ENA/GenBank Whole Genome Shotgun under the BioProject ID PRJNA438436 and is also available at https://doi.org/10.15454/NGBSPC91 as Genecatalog_with-note.fna.gz. The KO and CAZymes derived from the gene catalog are available in the same INRAE data repository and are in the Genecatalog_KO.tab and Genecatalog_CAZy.tab files, respectively.

The kmer-based kaiju v.1.8.0 (https://github.com/bioinformatics-centre/kaiju)31 approach was used for microbial taxonomic profiling of the trimmed shotgun metagenomes and the microbial gene catalog. The microbial gene catalog fasta, core group genes fasta, and paired reads after quality trimmed and decontamination from the horse genome were used and annotated against the NCBI nr_euk reference database (released on May 25, 2020) containing all proteins belonging to archaea, bacteria, fungi, microbial eukaryotes, and viruses for classification in Greedy run mode with -a greedy -e 3 allowing for maximum three mismatches. By default, Kaiju returned a NA if it could not find a taxonomic classification at certain ranks. The Kaijus tab-separated output files were imported into Krona and converted into HTML files. They are available at https://doi.org/10.15454/NGBSPC)91 under raw-samples.nr_euk.kaiju.html.

To circumvent the problem of false-positive species predictions due to misalignment and contamination, we defined an abundance threshold of 25%, where the top 25% abundant species in at least 50% of the individuals were retained using the filterfun_sample() function in the phyloseq R package. This reduced background noise but kept information on poorly-described species if they were ubiquitously found in the samples. The dominant phylotypes abundance, taxonomy, and the associated metadata are available at https://doi.org/10.15454/NGBSPC as Ecaomic_dominant_phylotypes_nonrariefied.rds.

The high-quality clean paired reads were aligned to the ResFinder database (accessed March 2018, v.4.0) using bowtie2 (v.2.3.5). ResFinder is a manually curated database of horizontally acquired antimicrobial resistance (AMR) genes. It contains many genes with numerous highly similar alleles (e.g., -lactamases). To avoid random assignment of read pairs on these high-identity alleles, the database was clustered at 95% of identity level, over 200bp using CDHIT-EST (options -G 0 -A 200 -d 0 -c 0.95 -T 6 -g 1)96 and a reference sequence was attributed to each cluster. Two successive mappings were done: (i) the first mapping with standard parameters (bowtie2 --end-to-end --no-discordant --no-overlap --no-dovetail no-unal) on the complete ResFinder database, and (ii) a second mapping on the clustered database using the reads from the first mapping, with less stringent parameters (bowtie2 --local --score-min L,10,0.8). More than 99% of the reads from the first mapping correctly aligned on a cluster reference sequence in the second mapping.

Counts from the second mapping were normalized by computing the RPKM (reads per kilobase reference per million bacterial reads) value for each ResFinder reference sequence. The RPKM values were calculated by dividing the mapping count on each reference by its gene length and the total number of bacterial read pairs for the samples and multiplying by 109. A minimum of 20 mapped reads was considered to validate the presence of an AMR gene cluster.

The microbiome R package allowed us to study global indicators of the gut ecosystem state, including measures of evenness, dominance, divergences, and abundance. Comparison of the gut -diversity indices between groups was performed by a two-sided Wilcoxon rank-sum test (pairwise comparison). BenjaminiHochberg multiple testing correction p<0.05 was set as the significance threshold for comparison between groups.

To estimate -diversity, BrayCurtis dissimilarity was calculated using the phyloseq R package. All samples were normalized using the rarefy_even_depth() function in the phyloseq R package, which is implemented as an ad hoc means to normalize features resulting from libraries of widely differing sizes. The PerMANOVA test (a non-parametric method of multivariate analysis of variance based on pairwise distances) was implemented using the adonis() function in the vegan R package and the pairwise.Adonis2() function from the pairwiseAdonis (v.0.4) R package tests the global association between ecological or functional community structure and groups. The model was adjusted by factors affecting the microbiome: age, sex, and dietary macronutrient intake.

The core group of genes in the catalog was defined as the genes present in all individuals.

The dominant core microbiome at the genus level was calculated using a detection threshold of 0.1% and a prevalence threshold of 95% in the microbiome R package.

The SParse InversE Covariance Estimation for Ecological Association Inference method (SPIEC-EASI)97 was used to identify sub-populations (modules) of co-abundance and co-exclusion relationships between dominant phylotypes and CAZy classes abundances matrices. Specifically, the method allows microorganisms and functions to interact differently, from bidirectional competition to mutualism or not interacting at all. The statistical method SPIEC-EASI comprises two steps: a transformation for compositionality correction of the feature matrices and estimation of the interaction graph from the transformed data using sparse inverse covariance selection. The sparse graphical modeling framework was constructed using the spiec.easi() function of the SpiecEasi package (v.1.1.1). The features were clustered using the method=mb, lambda.min.ratio=1e5, nlambda=100, pulsar.params=list (thresh=0.001). Regression coefficients from the SPIEC-EASI output were extracted and used as edge weights to generate a feature co-occurrence network R igraph package (v.1.2.6) and Cytoscape (v.3.8.2).

Data integration was carried out using several approaches and different combinations of datasets. Before the integration, we applied some additional pre-processing steps to our exploratory datasets. In particular, to eliminate intra-individual variability and focus on the differential signals between T1 and T0, we considered values (T1T0) for each of these datasets, namely biochemical assay data and metabolome acylcarnitine profiles, and gene expression data. For the transcriptome, we constructed a matrix of log-transformed expression values between T1 and T0 (e.g., the difference in log2-normalized expression between T1 and T0).

The integration of data was then performed using complementary methods and working with different datasets available, namely: (1) values of mitochondrial-related genes; (2) values of 1H NMR metabolites; (3) values of the biochemical assay metabolites; (4) values of plasmatic acylcarnitines; (5) the fecal SCFAs at T0; (6) the bacterial, ciliate protozoa and fungal loads at T0; (7) the dominant gut phylotypes at T0; (8) the CAZymes profiles at T0; (9) the KOs at T0, and the (10) athletic performance data.

As a first integration approach, a global non-metric multidimensional scaling (NMDS) ordination was used to extract and summarize the variation in microbiome composition using the metaMDS() function in the vegan R package. Stress values were calculated to determine the number of dimensions for each NMDS.

The explanatory datasets were then fit to the ordination plots using the envfit() function in the vegan R package98 with 10,000 permutations. Each covariates effect size and significance were determined, and all p-values derived from the envfit() function were adjusted BenjaminiHochberg. Variation partitioning was performed using the varpart() function in vegan in R.

The N-integration algorithm DIABLO of the mixOmics R package (http://mixomics.org/, v6.12.2) was used as a second integrative approach. It is to be noted that, in the case of the N-integration algorithm DIABLO, the variables of all the datasets were also centered and scaled to unit variance before integration. In this case, the relationships among all datasets were studied by adding a different categorical variable, e.g., the cardiovascular fitness of horses. Horses with poor cardiovascular fitness (n=8) were compared to horses with enhanced cardiovascular fitness (n=3). DIABLO seeks to estimate latent components by modeling and maximizing the correlation between pairs of pre-specified datasets to unravel similar functional relationships99. To predict the number of latent components and the number of discriminants, the block.splsda() function was used. The model was first fine-tuned using leave-one-out cross-validation by splitting the data into training and testing. Then, classification error rates were calculated using balanced error rates (BERs) between the predicted latent variables with the centroid of the class labels using the max. dist() function.

Finally, the DESeq2 (v.1.32.0)100 R package was used to test differential abundances analysis between groups for the dominant phylotypes, MAGs, and the genetic functionalities derived from KOs and CAZymes at the basal time. DESeq2 assumes counts can be modeled as a negative binomial distribution with a mean parameter, allowing for size factors and a dispersion parameter. The p-values were adjusted for multiple testing using the BenjaminiHochberg procedure. DESeq2 comparisons were run with the parameters fitType=parametric and sfType=Wald.

The validation set consisted of 22 pure-breed or half-breed Arabian horses (12 females, three males, and seven geldings; age: 9.21.27) not included in the experimental set to ensure that the observed effects were reproducible in a broader context (Supplementary Data20). Five animals were enrolled in a 160km endurance competition among the horses in the validation set, while 17 were in a 120km race. The management practices throughout the endurance ride and the International Equestrian Federation (FEI) compulsory examinations and the weather conditions, terrain difficulty, and altitude were that of the experimental set. All the participants enrolled in the study (experimental and validation set) competed in the same event in October 2015 in Fontainebleau (France). The cardiovascular capacity was created as described in the Performance measurement section as a composite of post-exercise heart rate, cardiac recovery time, and average speed during the race. Then, the HIGH, MEDIUM, and LOW groups were determined according to the interquartile range of the composite cardiovascular fitness values. HIGH included individuals with cardiovascular fitness values above the 75th percentile, LOW below the 25th percentile, and MEDIUM, the individuals ranging in between.

The PerMANOVA test was implemented by using pairwise.Adonis2() function from the pairwiseAdonis R package. The model was adjusted by factors affecting the microbiome: age and sex. The homogeneity of group dispersions (variance) was applied via the betadisp() function of the vegan package to account for the confounding dispersion effect. The one-way ANOVA with Tukeys honest significant differences (HSD) method for pairwise comparisons was performed using the TukeyHSD() function in the stats R package (v.3.6.2).

The PLS-DA was used to identify the key genera responsible for the differences in the groups using the mixOmics101 R package (v. 6.18.1). In addition, as PLS-DA loadings may be misleading with highly correlated variables, the differences in each relative genus abundance between the groups were quantified by DESeq2 R package.

Further information on research design is available in theNature Research Reporting Summary linked to this article.

Link:

Mining the equine gut metagenome: poorly-characterized taxa associated with cardiovascular fitness in endurance athletes | Communications Biology -...

Reports of menstrual disorders in Vaccine Adverse Event Reporting System (VAERS)

Figure1 (Flow diagram of case inclusion in this study) depicts the report selection procedure, including the reasons for exclusion. By November 12, 2021, 1,742,590 cases of adverse events were recorded in the VAERS database, and 60.94% of them were female. The category including menstrual disorders events 14,331 reports (1.36%), of which 13,118 (90.90%) were exposed to COVID19 vaccine and 13,13 (9.10%) were exposed to another vaccine. There were 1,047,452 (98.64%) other adverse events, 587,325 (56.07%) were exposed to COVID-19 vaccine and 460,130 (43.93%) were exposed to other vaccines.

Flow diagram of case inclusion in this study

Table 1 outlines the fundamental features of the 14,431 instances of menstrual disorders that have been documented. Reports of menstrual disorders are not mutually exclusive of each other, and multiple conditions may be encompassed in one adverse reaction report. The most prevalent event in both groups was Menstruation irregular, with 4626 cases (35.26%) reported in the COVID-19 vaccine group and 372 cases (28.33%) in the non-COVID-19 vaccine group. The COVID-19 vaccine group reported 2698 cases (20.57%) of Menstruation delayed,2088 cases (15.92%) of Intermenstrual bleeding, and Menorrhagia was reported only 28 cases (0.21%). The non-COVID-19 vaccine group reported 251 cases of Metrorrhagia (19.12%), 301 cases of Amenorrhoea (22.90%) and only 6 cases of Intermenstrual bleeding (0.46%).

The median age at the time of reporting was 35years in both groups, with a mean age of 36years in the COVID-19 vaccine group, which was greater than 16years in the non-COVID-19 vaccine group. A high proportion of the reported age was undetermined in both groups. Nearly half (48.82%) of the reported menstrual irregularities in the non-COVID-19 vaccine group were reported in the younger age group (<20years). Whereas in the COVID-19 vaccine group, a higher proportion (42.55%) was reported in the prime age group (3049years). After Fisher's exact test, there was a discrepancy between the two age groups (P value<0.001).

The interval from vaccine exposure to reported onset was reported in 11,681 cases (80.94%), with a median of 3.0days. There were 10,877 cases (82.92%) in the COVID-19 vaccine group with an adverse reaction reporting interval<100days. The non-COVID-19 vaccination group had an average reporting gap of 8days. After Fisher's exact test, there was a difference in the reporting interval between the two groups (P value<0.001). The following 20 non-COVID-19 vaccinations have been linked to recorded cases of menstrual disorders: Influenza virus vaccine(38 reports), Hepatitis B virus vaccine(51reports), Tetanus and diphtheria toxoids vaccine(9 reports), Pneumococcal vaccine (3 reports), Varivax-varicella virus live(14reports), Tetanus toxoid (1report), Human papillomavirus(1073 reports), Hepatitis A (12 reports), Anthrax vaccine (20 reports), Measles(1report), Measles, mumps and rubella virus vaccine(15 reports), Lyme disease vaccine(4reports), Rabies virus vaccine(2reports), Smallpox vaccine(2reports), Meningococcal conjugate vaccine(3 reports), Hepatitis A+hepatitis B vaccine(4 reports), Ebola Zaire vaccine(1 report), Meningococcal group b vaccine(1 report), Varicella-zoster vaccine(1 report), Unknow(57 reports).

The reported species of serious adverse events were mainly related to Death, Life-threatening, Emergency room visits, Hospitalized, Prolonged hospitalization, and Disability. There were no reports of deaths in the COVID-19 vaccine group, and a total of 1079 serious adverse events were reported (8.22%). 901 serious adverse events (68.62%) were documented in the non- COVID-19 vaccine group, three fatalities were reported which were the result of exposure to Human papillomavirus vaccine (2 reports) and Hepatitis B virus vaccine (1 report). More than one-third of the reports in both groups mentioned a prescription or nonprescription drugs that the vaccine recipient was taking at the time of vaccination and 1175 cases (8.20%) were suffering from a disease, while 6481 cases (45.22%) had been diagnosed with a disease prior to vaccination.

Table 2 describes the characteristics of the 13,118 menstrual disorders reported as a consequence of exposure to the COVID-19 vaccine. 9613 cases (73.28%) were reported in relation to Pfizer-Biontech, 2748 cases (20.95%) for Moderna and 742 cases (5.66%) for Janssen. The reported rates of other menstrual events differed between groups (p<0.001), except Intermenstrual bleeding, Hypomenorrhoea, Menorrhagia. Comparison between groups revealed that the distribution of reports of menstrual disorders by age group was heterogeneous (p<0.001). Except for the type of vaccine that could not be characterized, the remaining three groups reported significantly higher proportions in the 3039 age group than in other age groups, respectively accounting for 19.53%, 38.54%, and 31.67% of the total. The dose distribution by injected vaccine was likewise heterogeneous (P<0.001), with Dose 1 being reported at a significantly higher rate than Dose 2 and Dose 3. Only 1596 cases (16.60%) of vaccine recipients recovered from the adverse event when the adverse reaction information was reported, and 66.33% did unrecoverable at the time of reporting.

Analyses of the stated odds ratio for the COVID-19 vaccination incidents are shown in Tables 3, 4, 5, 6. The distribution of adverse events according to type (Menstrual disorder vs. other adverse reactions) and vaccination status (COVID-19 vaccines vs. other vaccines) is reported in Table 3. ROR estimated to be 7.83 (95% CI: 7.398.28), implies that COVID-19 vaccine may be a risk sign for the occurrence of events related to menstrual disorders. To further validate the correlation, three sensitivity analysis of the ROR were also performed. Firstly, aggregated by region of adverse reaction reporting (US vs. non-US) and vaccination status, ROR was 0.78(95% CI: 0.700.88), suggested that the reports of menstrual disorders after vaccination with the COVID-19 vaccine are unrelated to the regional distribution. Secondly grouped by age and type of report, compared the reported rates of adverse events associated with menstrual disorders in the 3049 age group with those in other age groups, ROR was 5.78(95% CI: 4.866.88). Finally, excluding reports of unknown age, ROR was 12.46(95% CI: 10.4114.92). Suggests that age may be a risk indicator for the event of menstrual disorders after vaccination with the COVID-19 vaccine.

Follow this link:

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS) - BMC Women's Health - BioMed...

MISSISSAUGA, ON, Oct. 5, 2022 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) has issued two final recommendations for TECENTRIQ (atezolizumab).

The first recommendation was that "Tecentriq be reimbursed by public drug plans after surgery and chemotherapy for the treatment of patients with stage II to stage IIIA non-small cell lung cancer (NSCLC) whose tumour is positive for programmed death-ligand 1 (PD-L1) in at least 50% of tumour cells and does not have an abnormal EGFR [epidermal growth factor receptor] or ALK [anaplastic lymphoma kinase] gene".2 The second recommendation was that, "Tecentriq, in combination with a platinum-based chemotherapy and etoposide, should be reimbursed by public drug plans for the [first-line] treatment of [adult patients with] extensive-stage small cell lung cancer (ES-SCLC)".1

The recommendations state that TECENTRIQ should be reimbursed for the adjuvant treatment of early-stage NSCLC and ES-SCLC patients if certain conditions are met.1,2 The two recommendations were made because CADTH acknowledged the benefit of TECENTRIQ in these lung cancer indications, and are a step towards public funding of TECENTRIQ for these two diseases.

"At the Lung Health Foundation, one of our key priorities is an increase in lung cancer survivorship, and we recognize that key to this is the advancement of innovative and publicly funded treatment options for patients diagnosed with lung cancer," says Peter Glazier, Executive Vice President, Lung Health Foundation. "Knowing how aggressive NSCLC and ES-SCLC cancers can be, it's critically important that patients have access to treatments such as TECENTRIQ."

NSCLC and SCLC are both subtypes of lung cancer. NSCLC accounts for approximately 88% of lung cancer cases in Canada, where approximately half of NSCLC cases are stage I-III at diagnosis.2 SCLC is 1 of 2 types of lung cancer; it is less common than nonsmall cell lung cancer, accounting for approximately 15% of patients with lung cancer. Most people with SCLC are diagnosed with extensive-stage cancer that has spread widely within the lungs, lymph nodes, and other parts of the body.1

"We need treatment options to manage this aggressive cancer," said Dr. Parneet Cheema, Medical Director of Cancer Care at William Osler Health System and Assistant Professor at University of Toronto. "The positive recommendations for Tecentriq to treat early stage NSCLC and advanced stage SCLC, are a major step forward towards public funding of this option for these patients."

"At Lung Cancer Canada, we see how lung cancer impacts thousands of patients, caregivers, and families everyday," says Shem Singh, Executive Director, Lung Cancer Canada. "Patients with early-stage NSCLC need treatment options that both work and allow them to spend quality time with their families. We welcome the approval of TECENTRIQ as this is an important step towards improving the lives of thousands of Canadians living with lung cancer."

"With the aggressive and rapidly progressing nature of ES-SCLC, available treatment options for this patient population are extremely limited," says Shem Singh, Executive Director, Lung Cancer Canada. "TECENTRIQ is one of the first treatments approved for this setting in decades, marking an important step forward for Canadians living with lung cancer. For this population of patients, every moment counts."

Roche Canada is pleased that the net clinical benefit of TECENTRIQ has been recognized by CADTH for both indications and is looking forward to partnering with the provinces and jurisdictions to help make medicines like TECENTRIQ more accessible to Canadians living with lung cancer.

About TECENTRIQ (atezolizumab)3

TECENTRIQ was authorized by Health Canada on January 14, 2022 as monotherapy for adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA (according to the AJCC 7th edition) NSCLC whose tumours have PD-L1 expression on 50% of tumour cells.3

TECENTRIQ has also been authorized by Health Canada for the first-line treatment of adult patients with ES-SCLC, in combination with carboplatin and etoposide3, since August 08, 2019.

TECENTRIQ is an Fc-engineered humanized immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Blocking these interactions release PD-L1/PD-1 pathway-mediated inhibition of the immune response, including reactivating the anti-tumour immune response.3

About Early Stage Non-Small Lung Cell Cancer (NSCLC) and Extensive Stage Small Cell Lung Cancer (ES-SCLC)1,2

Lung cancer is one of the most commonly diagnosed cancers and is the leading cause of cancer deaths in Canada, with non-small cell lung cancer (NSCLC) accounting for approximately 88% of lung cancer cases. Approximately half of NSCLC cases in Canada are stage I-III at diagnosis, and one-third of NSCLC patients have operable disease. Early-stage NSCLC (i.e., Stages I-IIIA per the AJCC 7th edition) is often asymptomatic. When patients do present with symptoms, these are usually non-specific and difficult to directly attribute to lung cancer. The most common symptoms include fatigue, cough, chest or shoulder pain, hemoptysis, weight loss, dyspnea, hoarseness, bone pain and fever.

Extensive stage (ES) disease is defined as disease that cannot be classified as limited. Approximately two-thirds of patients with SCLC have ES disease at diagnosis, which is associated with particularly poor prognosis.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights, help Roche deliver truly personalized healthcare. Roche aims to improve patient access to medical innovations by working with stakeholders across the entire healthcare sector to provide the best care for each person.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships, has become an industry-leading partner for medical insights, and has collaborated in artificial intelligence (AI) data-mining to fuel healthcare insights.

Roche Canada was founded in 1931, and employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics and Diabetes Care divisions in Laval, Quebec.

Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Globally, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI) for twelve consecutive years. Roche Canada is also actively involved in local communities through its charitable giving and partnerships with organizations and healthcare institutions that work together to improve the quality of life of Canadians.

For more information, please visit http://www.RocheCanada.com or follow us on Twitter @RocheCanada.

References:

1 pERC final recommendation, Atezolizumab (Tecentriq) - SCLC, September 20, 2022. Available at: https://www.cadth.ca/sites/default/files/DRR/2022/PC0277%20Tecentriq%20SCLC%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20Final.pdf. Last accessed September 23, 2022.

2 pERC final recommendation, Atezolizumab (Tecentriq) - NSCLC, September 20, 2022. Available at: https://www.cadth.ca/sites/default/files/DRR/2022/PC0269%20Tecentriq%20for%20NSCLC%20-%20CADTH%20Final%20Recommendation-Final-meta.pdf. Last accessed September 23, 2022.

3 Tecentriq Product Monograph, July 21, 2022.

SOURCE Roche Canada

Follow this link:

TECENTRIQ (atezolizumab) Receives CADTH Reimbursement Recommendations for the adjuvant treatment of early-stage Non-Small Lung Cell Cancer (NSCLC) and...